Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Reckitt Benckiser Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods, including medicines, in Australia. This Act was introduced to ensure that therapeutic goods are safe, of acceptable quality, and properly represented, thereby protecting public health. The Act is administered by the Therapeutic Goods Administration, a department of the Commonwealth of Australia’s Department of Health. The primary objective of the Act is to maintain and enhance the health and safety of the Australian population by regulating the supply, advertising, and quality of therapeutic goods. This legislative framework enables the TGA to control the importation, manufacture, and distribution of therapeutic goods, ensuring they meet stringent safety and quality standards. The 2015 consent under sections 14 and 14A of the Act, allowing the supply of Nurofen products with non-compliant labels, exemplifies the Act’s role in balancing public health protection with practical considerations in therapeutic goods regulation.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods, including medicines, in Australia. This Act applies to persons and entities involved in the supply or advertising of therapeutic goods within Australia, covering a broad range of products such as prescription and non-prescription medicines, medical devices, and complementary medicines. The Act encompasses the entire Commonwealth of Australia and is administered by the Therapeutic Goods Administration (TGA), an agency within the Department of Health. While the Act broadly applies to therapeutic goods, there are specific exclusions such as certain food products, cosmetics, and industrial gases, which fall under other regulatory frameworks. The Act's application can be extended or restricted through subordinate instruments, such as regulations and orders, which provide further detail on specific aspects of therapeutic goods regulation. This ensures that the Act can adapt to new developments and technological advancements in the therapeutic goods industry.

Key Provisions

The Therapeutic Goods Act 1989 (sections 14 and 14A) allows for specific consents to be granted in certain situations where therapeutic goods do not fully comply with the applicable legislative requirements. In this case, the Act enabled a delegate of the Secretary of the Department of Health to consent to the supply of two products by Reckitt Benckiser Australia that do not meet the labelling requirements as set out in Therapeutic Goods Order No. 69. Specifically, the consent allows for the supply of Nurofen for Children Baby 3+ Months strawberry flavour ibuprofen 40mg/mL oral liquid and Nurofen Tablets ibuprofen 200 mg, which lack the required advisory statement on their labels. Under this consent, the primary obligation imposed on the parties involved is the adherence to the specified condition that the consent applies only to the labels provided with the application dated 9 October 2015. This consent does not permit any broader deviation from the labelling requirements beyond the scope outlined. Additionally, the consent requires that the non-compliant products be supplied within a defined timeframe, from 20 October 2015 until 30 June 2016, after which the products must comply with the labelling requirements. The Therapeutic Goods Act 1989 does not explicitly outline offences or penalties for breaches of the consent terms in this particular context. However, failure to comply with the terms of the consent could potentially lead to broader regulatory consequences under the Act. This may include actions such as product recalls, fines, or other enforcement measures by the Therapeutic Goods Administration. The penalties for more general breaches of the Act can include substantial fines and, in some cases, imprisonment, reflecting the seriousness with which the regulation of therapeutic goods is treated.